How can survival be improved in localized osteosarcoma?
Despite numerous chemotherapy trials and the introduction of novel agents, survival in localized osteosarcoma, which plateaued in the mid-1980s, has been recalcitrant to our best efforts. The authors considered that a review of previous and current strategies that target survival might provide a direction for research efforts. Here, the focus is placed mainly on the reappraisal of previous mass chemotherapy trials and prognostic factors, in the hope of contriving a strategy to overcome the current stasis.
Jeon
Dae-Geun
DG
Department of Orthopedic Surgery, Korea Cancer Center Hospital, 215-4, Gongneung-dong, Nowon-gu, Seoul, 139-706, Korea. dgjeon@kcch.re.kr
Song
Won Seok
WS
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic / Q000639:trends; D006801:Humans; D012516:Osteosarcoma / Q000188:drug therapy* / Q000401:mortality*; D015996:Survival Rate / Q000639:trends
D000970:Antineoplastic Agents